Domestic cats are subject to multiple retrovirus infections. Two of these infections, feline leukemia virus (FeLV) and feline immunodeficiency virus (FIV) infections, are associated with progressive immune deficiency diseases. FeLV is an exogenously replicating type C oncovirus which is spread horizontally and is estimated to infect up to 50% of freeroaming cats in the United States (9) . The more recently isolated FIV is a member of the Lentivirinae subfamily of retroviruses and infects up to 14% of high-risk-group cats (17, 23) . The frequency of FIV and FeLV coinfection is 16% in FeLV-infected cats in the United States (22) . The prevalence of both oncovirus and lentivirus infections in cats creates a need for sensitive and specific diagnostic assays to differentiate between these viral infections, to accurately diagnose the infectious agent, and to elucidate possible cofactors of immune deficiency syndromes (18) .
Gallaher et al. (7) have proposed a general model for the structure of retrovirus transmembrane (TM) proteins that indicates several characteristic structural motifs shared by oncoviruses and lentiviruses. One such peptide domain is located at the apex of the TM protein and is predicted to be an immunodominant protein segment of the TM molecule (Imd-TM peptide). The proposed Imd-TM domain has a characteristic loop structure stabilized by disulfide bonding between vicinal cysteines (see Fig. 1 ) that is also critical for peptide antigenicity. Thus, this model suggests that retrovirus Imd-TM peptides should be useful as specific diagnostic reagents in peptide-specific serological assays, including assays to detect FIV-and FeLV-specific antibodies.
The respective Imd-TM peptides of several lentiviruses have been exploited as diagnostic reagents in serological assays for human immunodeficiency virus types 1 and 2, simian immunodeficiency virus, and equine infectious ane-* Corresponding author. mia virus (1, 3, 8, 12, 19, 21) . In each lentivirus system, the Imd-TM peptide displays a serological reactivity that develops rapidly to high titers after infection and that is maintained at high levels in long-term infections.
To date, the diagnostic potential of oncovirus Imd-TM peptides has not been evaluated in detail in any oncovirus system. Palker et al. (15) described an informative analysis of human T-cell leukemia virus I (HTLV-I) TM peptide antigenicity but did not assess the serological reactivity of the predicted HTLV-I Imd-TM peptide. Thus, the diagnostic potential of the oncovirus Imd-TM peptide remains to be determined. In this study, we have analyzed the antigenicity of the predicted FIV and FeLV Imd-TM peptides and evaluated their potential as diagnostic reagents in sitedirected serology to distinguish between FIV and FeLV infections in cats.
We initially modeled the TM proteins of FIV Petaluma (Fig. 1A ) (20) and FeLV (p1SE) (Fig. 1B) (16) . Potential amphipathic alpha-helical regions were predicted using the Amphi algorithm of Margalit et al. (11) . The results of these analyses were used to construct the proposed conformational model. The sequences of the predicted Imd-TM domains as proposed by Gallaher et al. (7) are shown in boxed areas. These Imd-TM peptides were synthesized for the serological assays described in the text. To examine further the potential of the FIV Imd-TM peptide as a diagnostic reagent, the kinetics of peptidespecific antibody responses in cats experimentally infected with FIV were examined. The serological data in Fig. 3 are presented as absorbance and not as the ratio of infected-cat serum reactivity to normal-cat serum reactivity. Figure 3 demonstrates that antibodies to the FIV Imd-TM peptide are detected early in FIV-infected cats; high titers are typically achieved within 2 weeks. In two cats (2531a and 2546a) infected by plasma transfer with 1,000 tissue culture infective doses of a field isolate of FIV, the antibody level was at least 200 times the normal cat reactivity to this peptide at some point between 3 and 6 weeks postinfection as reflected in the absorbance values obtained in peptide ELISA. Antibody titers in these two cats remained between 200 and 1,100 times normal cat levels for at least 18 weeks. Antibody levels in two cats (2104a and 2105a) infected with 10,000 tissue culture infective doses of FIV Petaluma from Crandel feline kidney cells increased very rapidly for the first 2 weeks, reached a plateau by 6 weeks, and remained between 50 and 200 times that of normal cats for at least 97 weeks. One cat (2528a) infected with 10,000 tissue culture infective doses of a field isolate of FIV grown in Crandel feline kidney cells experienced transient viremia (as determined by virus cultivation) and never developed detectable antibodies to the FIV Imd-TM peptide or to any FIV proteins (as determined by Western blot [immunoblot]), as was also the case with the control uninfected cat (2110a). This single FIV-inoculated cat was apparently able to clear the virus. Cats experimentally infected with FIV did not develop significant antibody cross-reactivity to the FeLV Imd-TM peptide during the course of infection (data not shown). This finding is not surprising, considering the lack of sequence homology between the Imd-TM peptides of FIV and FeLV. Thus, antibodies to the FIV Imd-TM peptide are generated early and maintained for extended periods in FIV infections, and they are not detectable in uninfected cats.
To investigate whether antibodies to the FeLV Imd-TM peptide might be detectable early postinfection, longitudinal The basis for the differential antigenicity of FIV and FeLV Imd-TM peptide domains is not certain. Our structural models (Fig. 1) for the FIV-TM Petaluma and FeLV-TM (pl5E) proteins are consistent with the general model presented earlier (7) . The observed strong antigenicity of the FIV Imd-TM peptide and the lack of antigenicity of the FeLV Imd-TM peptide are in agreement with the respective antigenic potentials predicted by the SurfacePlot algorithm (16) . Both the TM model and the SurfacePlot algorithm accurately predict a high antigenic potential for the FIV Imd-TM peptide. However, for human immunodeficiency virus type 1, simian immunodeficiency virus, and equine infectious anemia virus Imd-TM peptides the predictive schemes were in conflict with SurfacePlot, failing to predict that these peptide domains would constitute predominant epitopes. Clearly, sequence considerations alone can not reliably predict peptide-specific immunoreactivities, which must be determined experimentally.
In conclusion, these studies demonstrate that the predicted FIV Imd-TM peptide satisfies the criteria for utilization in site-directed serology, making it an excellent candidate for the development of a commercial diagnostic test (13, 14) . The FIV Imd-TM peptide is conserved in all sequenced isolates found in GenBank to date, and therefore a test based on this peptide can potentially have worldwide application.
